PD-L1 expression on tumor-infiltrating immune cells (IC), tumor mutation burden (TMB) and bulk transcriptome measurements were obtained before treatment with atezolizumab from 218 UC (IMvigor210), 83 NSCLC (POPLAR) and 78 RCC (IMmotion150) patients. Here, CD274 is linked to renal cell carcinoma.